Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical High Grade Squamous Intraepithelial Lesion: later-stage trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Cervical High Grade Squamous Intraepithelial Lesion: 2 US clinical trials tracked, none currently recruiting.
Cervical High Grade Squamous Intraepithelial Lesion is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Inovio Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition cervical-high-grade-squamous-intraepithelial-lesion
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Cervical High Grade Squamous Intraepithelial Lesion has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical High Grade Squamous Intraepithelial Lesion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical High Grade Squamous Intraepithelial Lesion is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Inovio Pharmaceuticals
NCT03721978
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Inovio Pharmaceuticals
NCT03185013
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical High Grade Squamous Intraepithelial Lesion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical High Grade Squamous Intraepithelial Lesion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical High Grade Squamous Intraepithelial Lesion page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Cervical High Grade Squamous Intraepithelial Lesion trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Inovio Pharmaceuticals sponsors the most Cervical High Grade Squamous Intraepithelial Lesion trials on record, review their full trial history before evaluating a specific study. See Inovio Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical High Grade Squamous Intraepithelial Lesion condition card totals 2 registered trials; most-linked intervention VGX-3100; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.